Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration‐resistant prostate cancer: A retrospective study

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|78|4|278-278

ISSN： 0270-4137

Source： THE PROSTATE, Vol.78, Iss.4, 2018-03, pp. : 278-278

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

By  

THE PROSTATE, Vol. 75, Iss. 8, 2015-06 ,pp. : 836-844

John Wiley & Sons Inc

Access to resources Recommend Favorite

Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

By  

Oncology, Vol. 91, Iss. 5, 2016-08 ,pp. : 267-273

Karger

Access to resources Recommend Favorite